Madison Reporter

Researchers at the University of Wisconsin–Madison have discovered new links between microbial bile acids and colon cancer risk. The study, led by Ting Fu from the School of Pharmacy, along with professors Jiaoyang Jiang and Dustin Deming from the School of Medicine and Public Health, highlights how two specific microbially-modified bile acids influence the development of tumors in the intestines through their interaction with a protein called farnesoid X receptor (FXR).

According to Fu, "Some microbial bile acids support FXR’s function, while others antagonize it." The research indicates that one bile acid supports FXR's function and slows tumor growth, while another inhibits FXR and fuels tumor growth. These findings were consistent across mouse models and organoids derived from human colon cancer patients.

The study's results are published in the Proceedings of the National Academy of Sciences. Postdoctoral researcher Xingchen Dong stated, "Understanding these complex mechanisms is a significant step toward improving early detection and developing targeted therapies for colorectal cancer."

Fu noted the complexity of gut microbes: “I think it’s fascinating that microbes can modify bile acids in this way and have such a big impact on our body.” The research was funded by several grants, including those from University of Wisconsin–Madison startup grants and the American Cancer Society.